Anna Frostegard

Company: Annexin Pharmaceuticals

Job title: Chief Scientific & Medical Officer

Seminars:

Roundtable Discussion: Navigating the Current Anti-VEGF Treatment & Paving the Path for the Future of Retinal Vascular Disease Drug Development for Improved Patient Care 3:10 pm

Preclinical Models Table: Discovering the latest preclinical models – in vivo, in vitro and ex vivo – being developed and implemented to accurately reflect the retinal vascular environment such as a 3D model of the blood retinal barrier plus expressing key physiological and biological characteristics Beyond VEGF Table: Exploring novel target pathways, beyond VEGF, for…Read more

day: Conference Day 1

Panel & Live Audience Discussion: Reviewing & Establishing the Translational Challenges of Accelerating Neovascularization Drugs into the Clinic & Beyond 1:30 pm

Capabilities and limitations of current pre-clinical models in allowing translatable research in nAMD / DME and DR Finding optimal clinical biomarkers and endpoints for different development stages in Wet AMD / DME/ DR Reviewing the need for updated regulatory guidelines for the measurements of efficacy and safety endpoints such as visual acuity, for the new…Read more

day: Conference Day 2

Discussing the Possibility & Potential of Systemically Administered Drugs for Retinal Vein Occlusion & Diabetic Eye Diseases 11:30 am

Discussing how systemic drugs for retinal vascular diseases can change the paradigm of ophthalmic treatment Delving into the mechanism of disease for better insights when treating new therapeutic targets Sharing clinical data to showcase that patients with retinal vascular indications can be treated without anti-VEGFRead more

day: Conference Day 1